CeQur, a company focused on simplifying mealtime insulin delivery for people with diabetes, announced the closing of a $100 million Series E financing round. The funding reflects continued investor confidence in the company’s commercial progress, clinical results, and the growing adoption of its CeQur Simplicity wearable insulin patch.
The company said the financing marks the start of its next phase of expansion and will be used to accelerate growth across its commercial operations. CeQur plans to expand its field sales organization and strengthen relationships with healthcare providers and diabetes specialists seeking simpler insulin delivery solutions for patients.
CeQur Simplicity is a discreet, injection-free wearable patch designed to simplify mealtime insulin dosing. The company is preparing to broaden the product line with extended seven-day wear capabilities and both one-unit and two-unit dosing options, enabling it to serve a wider patient population.
According to the company, more than 85% of claims for CeQur Simplicity are covered as a pharmacy benefit, with average monthly copays below $45. Clinical studies have shown that nearly 90% of patients reported better adherence to their insulin regimen compared with multiple daily injections, while also achieving improved A1C levels and better time-in-range outcomes.
CeQur believes its combination of new FDA clearances, clinical evidence, and fresh capital positions the company to further expand access to simpler insulin delivery options for adults living with diabetes.
KEY QUOTES:
“We have the commercial infrastructure, new clinical evidence. and an exciting pipeline. Now we have the capital to accelerate our growth. CeQur Simplicity is ready to reach every patient and physician who wants to simplify their insulin delivery and improve their diabetes management.”
Bradley Paddock, President and Chief Executive Officer, CeQur
“This financing is a direct reflection of what the CeQur team has built and the confidence our investors have placed in CeQur’s growth trajectory. We are grateful for that trust and committed to deploying this capital to deliver on the full potential of CeQur Simplicity for patients, for providers, and for every investor who believes in our mission.”
Mike Rubino, Chief Financial Officer, CeQur
